Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort

被引:37
|
作者
Pammer, Lorenz M. [1 ]
Lamina, Claudia [1 ]
Schultheiss, Ulla T. [2 ,3 ,4 ,5 ]
Kotsis, Fruzsina [2 ,3 ,4 ,5 ]
Kollerits, Barbara [1 ]
Stockmann, Helena [6 ]
Lipovsek, Jan [2 ,3 ]
Meiselbach, Heike [7 ]
Busch, Martin [8 ]
Eckardt, Kai-Uwe [6 ,7 ]
Kronenberg, Florian [1 ]
机构
[1] Med Univ Innsbruck, Inst Genet Epidemiol, Dept Genet & Pharmacol, Schopfstr 41, A-6020 Innsbruck, Austria
[2] Univ Freiburg, Fac Med, Inst Genet Epidemiol, Freiburg, Germany
[3] Univ Freiburg, Med Ctr, Inst Genet Epidemiol, Freiburg, Germany
[4] Univ Freiburg, Dept Med Nephrol & Primary Care 4, Fac Med, Freiburg, Germany
[5] Univ Freiburg, Med Ctr, Freiburg, Germany
[6] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany
[7] Friedrich Alexander Univ Erlangen Nurnberg, Dept Nephrol & Hypertens, Erlangen, Germany
[8] Friedrich Schiller Univ Jena, Dept Internal Med 3, Jena, Germany
关键词
cardiovascular disease; chronic kidney disease; metabolic syndrome; mortality; prospective cohort study; CORONARY-HEART-DISEASE; RISK; DEATH; TRIGLYCERIDES; INFLAMMATION; MECHANISMS; PROFILE; GCKD; CKD;
D O I
10.1111/joim.13355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Metabolic syndrome with its key components insulin resistance, central obesity, dyslipidaemia, and hypertension is associated with a high risk for cardiovascular events and all-cause mortality in the general population. However, evidence that these findings apply to patients with chronic kidney disease (CKD) with moderately reduced estimated glomerular filtration rate and/or albuminuria is limited. Objectives We aimed to investigate the association between metabolic syndrome and its components with all-cause mortality and cardiovascular outcomes in CKD patients. Methods Prospective observation of a cohort of 5110 CKD patients from the German Chronic Kidney Disease study with 3284 (64.3%) of them having a metabolic syndrome at baseline. Results During the follow-up of 6.5 years, 605 patients died and 650 patients experienced major cardiovascular events. After extended data adjustment, patients with a metabolic syndrome had a higher risk for all-cause mortality (hazard ratio [HR] = 1.26, 95% confidence interval [CI]: 1.04-1.54) and cardiovascular events (HR = 1.48, 95% CI: 1.22-1.79). The risk increased steadily with a growing number of metabolic syndrome components (increased waist circumference, glucose, triglycerides, hypertension and decreased HDL cholesterol): HR per component = 1.09 (95% CI: 1.02-1.17) for all-cause mortality, and 1.23 (95% CI: 1.15-1.32) for cardiovascular events. This resulted in hazard ratios between 1.50 and 2.50 in the case of four or five components present. Analysis of individual components of metabolic syndrome showed that the glucose component led to the highest increase in risk for all-cause mortality (HR = 1.68, 95% CI: 1.38-2.03) and cardiovascular events (HR = 1.81, 95% CI: 1.51-2.18), followed by the HDL cholesterol and triglyceride components. Conclusions We observed a high prevalence of metabolic syndrome among patients with moderate CKD. Metabolic syndrome increases the risk for all-cause mortality and cardiovascular events. The glucose and lipid components seem to be the main drivers for the association with outcomes.
引用
收藏
页码:1219 / 1232
页数:14
相关论文
共 50 条
  • [1] Association of Kidney Histopathology to Major Adverse Cardiovascular Events in Adults With Chronic Kidney Disease: An Analysis of the Boston Kidney Biopsy Cohort
    Buckley, Leo F.
    Srivastava, Anand
    Amodu, Afolarin
    Palsson, Ragnar
    Shah, Amil M.
    Waikar, Sushrut
    CIRCULATION, 2019, 140
  • [2] Cardiovascular-Kidney-Metabolic Syndrome: Association with Adverse Events After Major Noncardiac Surgery
    Roth, Sebastian
    M'Pembele, Rene
    Matute, Purificacion
    Kotfis, Katarzyna
    Larmann, Jan
    Buse, Giovanna Lurati
    ANESTHESIA AND ANALGESIA, 2024, 139 (03): : 679 - 681
  • [3] Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease
    Barayev, Odeya
    Hawley, Chelsea E.
    Wellman, Helen
    Gerlovin, Hanna
    Hsu, Whitney
    Paik, Julie M.
    Mandel, Ernest I.
    Liu, Christine K.
    Djousse, Luc
    Gaziano, J. Michael
    Gagnon, David R.
    Orkaby, Ariela R.
    JAMA NETWORK OPEN, 2023, 6 (12) : E2346373
  • [4] Association of metabolic syndrome and chronic kidney disease
    Scurt, Florian G.
    Ganz, Maximilian J.
    Herzog, Carolin
    Bose, Katrin
    Mertens, Peter R.
    Chatzikyrkou, Christos
    OBESITY REVIEWS, 2024, 25 (01)
  • [5] The Association Between Serum Potassium and Major Adverse Cardiovascular Events in Patients With Chronic Kidney Disease
    Yang, Alex
    Luo, Jiacong
    Jensen, Donna E.
    Brunelli, Steven M.
    CIRCULATION, 2014, 130
  • [6] Association of chronic venous disease with major adverse cardiovascular events
    Singh, Tejas P.
    Velu, Ramesh B.
    Quigley, Frank
    Golledge, Jonathan
    JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2022, 10 (03) : 683 - 688
  • [7] Chronic Kidney Disease is Associated With Increased Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Arterial Disease
    Westin, Gregory G.
    Armstrong, Ehrin J.
    Chen, Debbie C.
    Laird, John R.
    CIRCULATION, 2014, 130
  • [8] Association between metabolic syndrome and chronic kidney disease
    Kawada, Tomoyuki
    CLINICA CHIMICA ACTA, 2018, 478 : 44 - 44
  • [9] Association between chronic kidney disease and metabolic syndrome
    Orisaka, M.
    Kawamura, K.
    Nakamura, M.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A155 - A155
  • [10] LONGITUDINAL ASSOCIATION BETWEEN IRON STORES BIOMARKERS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN CHRONIC KIDNEY DISEASE
    Le Gall, Lisa
    Sirna, Federico
    Combe, Christian
    Massy, Ziad
    Lange, Celine
    Stengel, Benedicte
    de Pinho, Natalia Alencar
    Harambat, Jerome
    Leffondre, Karen
    Prezelin-Reydit, Andmathilde
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I497 - I498